Prometheus Labs

Executive Summary

Prometheus Labs is a specialty clinical diagnostics company focused on precision-guided care for inflammatory bowel disease (IBD) and other gastrointestinal disorders. Since its founding in 1995, the company has developed a portfolio of testing services that enable clinicians to improve patient outcomes across the disease journey—from early interception and stratification to therapy selection and monitoring. Operating as a private entity based in San Diego, Prometheus Labs leverages proprietary biomarkers and advanced analytics to address significant unmet needs in IBD management, where treatment response varies widely among patients. The company's tests aim to reduce trial-and-error prescribing, lower healthcare costs, and enhance quality of life for millions of patients worldwide. With the global IBD diagnostics market projected to grow steadily, Prometheus Labs is well-positioned to capitalize on the shift toward personalized medicine, though it faces competition from larger reference laboratories and emerging molecular diagnostic players. Its long-standing presence and specialized focus provide a competitive moat, but further investment in commercialization and clinical evidence will be critical to sustaining growth.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation IBD biomarker panel65% success
• Q2 2026Publication of key clinical validation study70% success
• Q1 2027Strategic partnership with major pharmaceutical company50% success